Dermira Completes Patient Enrollment for Third CIMZIA® (certolizumab pegol) Phase 3 Clinical Trial in Psoriasis Program and Updates Guidance for Release of Topline Data
January 08, 2016 01:00 ET
|
Dermira, Inc.
Enrollment for All Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Plaque Psoriasis Completed Dermira Plans to Announce Topline Data for Phase 3 Trials by End of First Quarter...
Dermira Provides DRM01 and DRM04 Development Program Updates
January 07, 2016 16:05 ET
|
Dermira, Inc.
Enrollment Completed in DRM01 Phase 2b Acne Trial; Topline Data Expected in 2Q16 Topline Data for DRM04 Phase 3 Hyperhidrosis Program Expected Mid-2016 MENLO PARK, Calif., Jan. 07, 2016 (GLOBE...
Dermira Added to NASDAQ Biotechnology Index
December 15, 2015 07:00 ET
|
Dermira, Inc.
MENLO PARK, Calif., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to...
Dermira Completes Patient Enrollment for Second CIMZIA(R) (certolizumab pegol) Phase 3 Clinical Trial in Psoriasis Program
November 19, 2015 07:00 ET
|
Dermira, Inc.
MENLO PARK, Calif., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists...
Dermira Reports Third Quarter 2015 Financial Results and Provides Corporate Update
November 10, 2015 16:24 ET
|
Dermira, Inc.
MENLO PARK, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists...
Dermira Completes Patient Enrollment for First CIMZIA(R) (Certolizumab Pegol) Phase 3 Clinical Trial in Psoriasis Program
October 12, 2015 16:21 ET
|
Dermira, Inc.
MENLO PARK, Calif., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists...
Dermira Presents Data From DRM01 Phase 2a Trial at European Academy of Dermatology and Venereology
October 07, 2015 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., Oct. 7, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and...
Dermira Elects Kathleen Sebelius to Board of Directors
September 30, 2015 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists...
Dermira to Present Data for DRM01 Acne Program at EADV Congress 2015
September 29, 2015 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists...
Skin Disposition Study Results for Dermira's DRM01 Program in Acne Presented at International Dermatology Meeting
September 10, 2015 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists...